{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:00:37Z","timestamp":1781658037073,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1124\/dmd.110.033951","type":"journal-article","created":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T02:07:40Z","timestamp":1280455660000},"page":"1962-1966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors"],"prefix":"10.1016","volume":"38","author":[{"given":"Tarek","family":"Mekhail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaswamy","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Pursley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Patricia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Ganapathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.110.033951_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.110.033951_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-200645010-00003","article-title":"Mass balance studies, with a focus on anticancer drugs","volume":"45","author":"Beumer","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.110.033951_bib3","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1021\/jm051106d","article-title":"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor","volume":"49","author":"Bhide","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.110.033951_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1535-7163.MCT-09-0472","article-title":"The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases","volume":"9","author":"Bhide","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.110.033951_bib5","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1021\/jm7013309","volume":"51","author":"Cai","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.110.033951_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1124\/dmd.110.033951_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.110.033951_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.110.033951_bib9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors\u2014a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.110.033951_bib10","series-title":"Proceedings of the 20th EORTC-NCI-AACR Symposium on \u201cMolecular Targets and Cancer Therapeutics\u201d; 2008 October 21\u201324; Geneva, Switzerland. Abstr 429","article-title":"Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors","author":"Hurwitz","year":"2008"},{"key":"10.1124\/dmd.110.033951_bib11","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1158\/1078-0432.CCR-08-0509","article-title":"Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma","volume":"14","author":"Huynh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.110.033951_bib12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.110.033951_bib13","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.110.033951_bib14","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/dmd.110.033951_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.110.033951_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00280-009-1002-0","article-title":"Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate","volume":"65","author":"Marathe","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.110.033951_bib17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.110.033951_bib18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1634\/theoncologist.11-7-753","article-title":"Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions","volume":"11","author":"Morabito","year":"2006","journal-title":"Oncologist"},{"key":"10.1124\/dmd.110.033951_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.110.033951_bib20","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-04-2427","article-title":"Endogenous inhibitors of angiogenesis","volume":"65","author":"Nyberg","year":"2005","journal-title":"Cancer Res"},{"issue":"15s","key":"10.1124\/dmd.110.033951_bib21","article-title":"An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) (abstract)","volume":"27","author":"Raoul","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.110.033951_bib22","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.110.033951_bib23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat Rev"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624025285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624025285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.110.033951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:53:18Z","timestamp":1739897598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624025285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0090955624025285"],"URL":"https:\/\/doi.org\/10.1124\/dmd.110.033951","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.110.033951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}